1301214-60-7

Basic information

• Product Name: 1-oxo-1,8a-dihydroisoquinoline-6-carboxylic acid
• Synonyms: 1-oxo-1,8a-dihydroisoquinoline-6-carboxylic acid;1 - Hydroxyisoquinoline - 6 - carboxylic acid;1-Hydroxy-2-azanaphthalene-6-carboxylic acid, 6-Carboxy-1-hydroxyisoquinoline;1-Oxo-1,2-dihydroisoquinoline-6-carboxylic acid;1-oxoisoquinoline-2(1H)-carboxylic acid
• CAS NO: 1301214-60-7
• Molecular Formula: C10H7NO3
• Molecular Weight: 189.16748
• Mol File: 1301214-60-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-oxo-1,8a-dihydroisoquinoline-6-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-oxo-1,8a-dihydroisoquinoline-6-carboxylic acid(1301214-60-7)
• EPA Substance Registry System: 1-oxo-1,8a-dihydroisoquinoline-6-carboxylic acid(1301214-60-7)

Safety Data

• Hazardous Substances Data: 1301214-60-7(Hazardous Substances Data)

Usage

Molecular structure

A complex fused-ring system consisting of an isoquinoline core with a carboxylic acid functional group attached to the 6-position.

Derivative of isoquinoline

It is derived from the nitrogen-containing heterocyclic compound isoquinoline, which is known for its various biological activities and potential pharmaceutical applications.

Carboxylic acid group

The presence of the carboxylic acid (-COOH) group in the structure suggests that the compound is likely to be acidic, which may contribute to its potential pharmaceutical or medicinal properties.

Potential pharmaceutical applications

Due to its structure and the presence of the carboxylic acid group, 1-oxo-1,8a-dihydroisoquinoline-6-carboxylic acid may have potential applications in the pharmaceutical industry, particularly in the development of new drugs.

Relevance to research fields

The compound's structure and properties make it of interest to researchers in the fields of organic chemistry, pharmaceuticals, and drug discovery, as it may provide insights into the design and synthesis of new compounds with therapeutic potential.

Upstream product

• 34784-05-9 6-bromo-isoquinoline 
• 205055-63-6 6-bromo-1-chloroisoquinoline 
• 223671-16-7 6-bromoisoquinoline nitrogen oxide 
• 1184920-35-1 methyl 1-oxo-1,2-dihydroisoquinoline-6-carboxylate 
• 1034558-65-0 (E)-1-bromo-3-(2-isocyanatovinyl)benzene 
• 14473-91-7 3-Bromocinnamic acid 
• 82827-09-6 6-bromo-2H-isoquinoline-1-one 

Relevant articles and documents

INHIBITORS OF ENL/AF9 YEATS

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

RHO KINASE INHIBITORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase-mediated disorders selected from hypertension, atherosclerosis, restenosis, stroke, myocardial infarction, heart failure, coronary artery disease, peripheral artery disease, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, erectile dysfunction, renal disease, organ failure, asthma, glaucoma, cancer, Alzheimer's disease, multiple sclerosis, spinal cord injury, neuropathic pain, rheumatoid arthritis, psoriasis inflammatory bowel disease, and combinations of such disorders.

N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions there-of; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal